Add-on Reparixin in Adult Patients With ARDS
This study is for adults with **Acute Respiratory Distress Syndrome (ARDS)**, a condition where the lungs can't provide enough oxygen to the body. The study is testing a drug called **reparixin** to see if it helps improve lung function and reduce inflammation. Patients will be randomly assigned to receive either reparixin or a placebo (a fake treatment that looks like the drug but isn't) for 14 days. This study is **double-blinded**, meaning neither the patients nor the doctors know who is getting reparixin and who is getting the placebo. Patients will receive the treatment in the form of tablets that can be given through a tube or swallowed, if possible. The study includes several periods: screening, treatment, and follow-ups up to 60 days or until the patient leaves the hospital. Participants must be over 18, currently on a ventilator, and have specific lung conditions. There are several health conditions and situations that would make someone not eligible for the study.

• The study lasts up to 60 days, with treatment for 14-21 days.
• Patients must be on a ventilator and have specific lung conditions.
• The trial compares reparixin to a placebo, with no cost to participants.